HRMY logo

HRMY Harmony Biosciences Holdings, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$33.76
-0.04 (-0.12%)

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, …

Market Cap: $1.98Bwww.harmonybiosciences.com

Price

No data yet.

Social Signal Score

54
5d
50
1 mentions
—
30d
50
4 mentions
—
60d
58
14 mentions
—
90d
58
15 mentions
—
news: 15

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 3Sell 2Strong Sell 0
Avg price target$49.57+46.8%
Low $34Median $49High $70
Current Consensus

Revenue

$268.92M
$0.00$89.64M$179.28M$268.92M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$3.20
$2.96–$3.57
4 analysts
FY2026
$3.71+16% YoY
$3.29–$4.00
7 analysts
FY2027
$4.01+8% YoY
$3.12–$4.91
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jeffrey Dayno
Sector
Healthcare
Industry
Biotechnology
Employees
293
Beta
0.98
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
4.99
www.harmonybiosciences.com